AFP and hepatocellular carcinoma: Our findings may illuminate a novel direction suggesting that attention may be warranted toward the AFP response in future clinical trials of neoadjuvant therapy for HCC, with the aim to ascertain its capacity to serve as an efficacious marker of the oncological advantage derived from neoadjuvant therapy.